Physician profile
Columbus Brown
NPI 1558321612
$18,035.27
in general payments reported to CMS, 2019-2025
39 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,360 · 2020: $3,591 · 2021: $3,022 · 2022: $2,295 · 2023: $1,993 · 2024: $2,039 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,588 · Consulting Fee: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,587.78 |
| Consulting Fee | $180.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,556.66 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $3,485.40 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $1,669.36 | 2019-2025 | Benlysta |
| Pfizer INC. | $1,323.94 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,185.82 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $939.80 | 2019-2025 | Tremfya |
| Horizon Therapeutics Plc | $933.28 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $643.72 | 2021-2025 | Saphnelo |
| Ucb, INC. | $630.74 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $612.35 | 2019-2025 | |
| Lilly USA, LLC | $524.78 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $431.40 | 2019-2025 | Orencia |
| Mallinckrodt Enterprises LLC | $271.76 | 2019 | |
| Aurinia Pharma U.S., INC. | $255.83 | 2021-2024 | Lupkynis |
| Genentech USA, INC. | $175.11 | 2020-2025 | Gazyva |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Columbus Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.